Advertisement
Australia markets closed
  • ALL ORDS

    7,285.10
    -12.60 (-0.17%)
     
  • ASX 200

    7,073.20
    -14.10 (-0.20%)
     
  • AUD/USD

    0.6668
    +0.0059 (+0.89%)
     
  • OIL

    76.33
    +0.37 (+0.49%)
     
  • GOLD

    2,080.80
    +23.60 (+1.15%)
     
  • Bitcoin AUD

    58,116.84
    +1,523.75 (+2.69%)
     
  • CMC Crypto 200

    800.56
    +9.00 (+1.14%)
     
  • AUD/EUR

    0.6126
    +0.0064 (+1.06%)
     
  • AUD/NZD

    1.0754
    +0.0024 (+0.23%)
     
  • NZX 50

    11,367.51
    +37.31 (+0.33%)
     
  • NASDAQ

    15,996.21
    +48.35 (+0.30%)
     
  • FTSE

    7,529.35
    +75.60 (+1.01%)
     
  • Dow Jones

    36,210.79
    +259.90 (+0.72%)
     
  • DAX

    16,397.52
    +182.09 (+1.12%)
     
  • Hang Seng

    16,830.30
    -212.58 (-1.25%)
     
  • NIKKEI 225

    33,431.51
    -55.38 (-0.17%)
     

1 Beaten-Down Stock That Has a Lot to Prove in 2023

1 Beaten-Down Stock That Has a Lot to Prove in 2023

The past several years have been brutal for biotech company Bluebird bio (NASDAQ: BLUE). Shares of the gene-editing specialist are down by 85% since early 2020 as it has had to deal with clinical and regulatory setbacks, not to mention the marketwide headwinds that have impacted all equities.